

[THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION NO. 596/2014 (AS INCORPORATED INTO UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED BY VIRTUE OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN]

14 January 2026

Truetide plc
("Truetide" the "Company" or the "Group")

Investment update - Paraytec

Truetide (AIM: TRUE) announces an update on one of its investee companies, Paraytec Limited ("Paraytec"). Truetide has a 100% interest in Paraytec.

Paraytec has initiated a focused development program to establish a high-throughput, real-time fluorescent assay for alpha-synuclein fibril formation using the CX300 detection system.

Alpha-synuclein aggregation is widely regarded as the central pathological process in Parkinson's disease and other neurodegenerative diseases. Despite intensive industry efforts, no disease-modifying therapy has yet reached the market, in part due to the absence of robust, rapid and cost-effective screening tools capable of identifying molecules that prevent or reverse pathological aggregation.

The planned work comprises:

- production and purification of recombinant wild-type and selected pathogenic mutant alpha-synuclein proteins;
- optimisation of site-specific fluorescent labelling compatible with real-time measurement on the CX300 instrument;
- full validation of the assay across multiple alpha-synuclein variants; and
- preparation of a technical methods paper and presentation at leading international synucleinopathy conferences in 2026, supported by collaboration with Professor Oliver Bandmann (Sheffield Institute for Translational Neuroscience (SiTRAN)).

In the event of a successful completion, Paraytec expects to possess a proprietary, accurate, rapid and low-cost assay that is currently unavailable from any commercial source in a format optimised for the CX300 platform. The directors of Paraytec believe that this assay has the potential to become a preferred screening tool for pharmaceutical and biotechnology companies active in the synucleinopathy field.

The combination of high sensitivity, real-time kinetics, and low sample consumption positions the CX300 system to capture meaningful market share in what is a multi-billion-dollar drug discovery segment. Initial commercialisation routes under active consideration include reagent kit sales, fee-for-service screening and strategic partnerships with instrument vendors and therapeutic developers.

The Board of Truetide views this investment by Paraytec as a high-return opportunity to establish clear technical differentiation for the CX300 platform in one of the most commercially attractive areas of neurodegenerative disease research.

A further announcement will be made upon completion of the program and publication of the validation data.

Trevor Brown, CEO of Truetide, commented:

"Paraytec remains close to making the scientific and commercial breakthrough via its CX300 technology, that the directors of Truetide hope for. Although somewhat protracted, the development work for a rapid Gram test continues, this new program to establish a high-throughput, real-time fluorescent assay for alpha-synuclein fibril formation significantly increases Paraytec's exposure to the possibility of eventual commercialisation of the CX300."

Truetide plc

Trevor Brown, Chief Executive Officer
Viv Hallam, Executive Director

Tel: 01738 587555

Allenby Capital Limited (Nominated Adviser and Joint Broker)
James Reeve / Ashur Joseph

Tel: 020 3328 5656

AlbR Capital Limited (Joint Broker)
Duncan Vasey / Lucy Williams

Tel: 020 7469 0936

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

PFUBJMBTMTIBTRF